Emcure, an Indian pharmaceutical giant, once again requested the dismissal of a $950 million trade secrets lawsuit lodged by Seattle-based biotech company HDT Bio Corp., during a proceeding on Thursday. Emcure contended that HDT’s claim alleging the theft of trade secrets is a duplication of a concurrent arbitration process in London.
The substantial lawsuit stems from accusations by HDT Bio Corp. that Emcure illicitly appropriated trade secrets. However, Emcure recently pushed back with a plea to a Washington federal judge, arguing that this ongoing dispute mirrors another underway in the UK.
An account of this legal confrontation was reported by Law360 correspondent Kelly Lienhard. For additional information and further developments in this litigation, the comprehensive report is available at Law360.